FASENRA is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Benralizumab.
| Product ID | 0310-1730_220fd267-9bb7-49d6-a86f-a0fd6718ac46 |
| NDC | 0310-1730 |
| Product Type | Human Prescription Drug |
| Proprietary Name | FASENRA |
| Generic Name | Benralizumab |
| Dosage Form | Injection, Solution |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2017-11-14 |
| Marketing Category | BLA / BLA |
| Application Number | BLA761070 |
| Labeler Name | AstraZeneca Pharmaceuticals LP |
| Substance Name | BENRALIZUMAB |
| Active Ingredient Strength | 30 mg/mL |
| Pharm Classes | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC],Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2017-11-14 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA761070 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2017-11-14 |
| Marketing Category | BLA |
| Application Number | BLA761070 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2017-11-14 |
| Ingredient | Strength |
|---|---|
| BENRALIZUMAB | 30 mg/mL |
| SPL SET ID: | da6aca1a-19ed-44a4-abb7-696c7d58b784 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0310-1730 | FASENRA | Benralizumab |
| 0310-1830 | FASENRA | Benralizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() FASENRA 98375565 not registered Live/Pending |
AstraZeneca AB 2024-01-25 |
![]() FASENRA 87128498 5612391 Live/Registered |
AstraZeneca AB 2016-08-05 |